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Introduction: Our aim is to examine the clinical value of spectral-domain optical coher-
ence tomography (Spectralis OCT) to detect retinal nerve fibre layer defects in patients
with clinically defined Alzheimer‘s disease (AD).
Material and Methods: This cross-sectional study included 22 patients with AD (mean
age: 75.9±6.1 years) and 22 healthy age- and sex-matched controls. Neuro-ophthalmologic
examinations and a series of high-resolution OCT examinations of the peripapillary retinal
nerve fiber layer (RNFL) thickness using the Spectralis 3.5-mm circle scan protocol with
ART-Modus and eye tracking were obtained, and compared to age- and sex-matched healthy
control subjects.
Results: Patients with AD showed a significant decrease in RNFL thickness in the nasal
superior sector compared to the control group (101.0±18.18µm versus 122.8±28.08µm;
P <0.0001). In all other sectors, independently of disease duration, no significant differ-
ence in RNFL thickness compared to controls was detected. Using the advanced age- and
gender-matched measurement model, 32 out of 42 eyes (76.19%) as pathologic with 67
abnormal sectors were detected.
Discussion: As examined by spectral-domain OCT, patients with mild to moderate stages
of AD showed a significant reduction of RNFL thickness in the nasal superior sector.
Nevertheless, successive studies are needed.
Keywords: Alzheimer’s disease, optical coherence tomography, retinal nerve fiber layer, retinal nerve fiber layer
thickness, dementia
INTRODUCTION
Alzheimer’s disease (AD) is a long term progressive neurode-
generative disease with a large variability between subjects (1).
The pathology of AD may evolve in the brain years before clin-
ical dementia, i.e., progressive loss of memory and other cogni-
tive functions, associated with functional decline and behavioral
disturbances, is recognized. Thus, a major research focus is on
diagnosing AD in the stage of mild cognitive impairment (MCI),
i.e., when gradual impairment of memory and other cognitive
function develops that precedes the point at which significant
interference in daily activities occurs. To support the clinical diag-
nosis at this heterogeneous clinical stage, biomarkers have been
validated and included into the clinical diagnostic criteria (2, 3),
which consist of magnetic resonance imaging (MRI) to show the
atrophy of the medial temporal lobe (4, 5), positron emission
tomography (PET) to detect changes in the metabolism of glu-
cose (5, 6) and Aβ deposition in the brain (7, 8) as well as the
cerebrospinal fluid analysis (CSA) to measure tau protein and Aβ
peptide levels (9, 10).
A novel ophthalmic imaging method, optical coherence tomog-
raphy (OCT), has been discussed to be useful for the detection
of early stages of AD (11–13). OCT allows for a non-invasive
visualization of axons of the central nervous system (CNS) provid-
ing cross-section imaging of the retina and is able to measure the
retinal nerve fiber layer thickness (RNFLT) (14, 15). It has been
used for the diagnosis of many retinal and optic nerve diseases
including the glaucomas (16–23). The human eye is an embry-
ological protrusion of the brain, and the nerves and axons of the
retinal nerve fiber layer (RNFL) are similar to those in the brain.
An intriguing hypothesis has been proposed that the neurode-
generative process in AD may also affect the RNFL of the eye as
well. Years ago, histopathological studies suggested that the RNFL
was not affected by AD (24, 25). In contrast, previously published
OCT studies carried out by traditional time-domain OCT (TD-
OCT) devices claimed to be able to detect a loss of the RNFL
in patients with AD (12, 13, 26–28). The observed reduction in
RNFLT was evident in MCI and could therefore be used to dis-
criminate between different stages of AD (11–13). It was shown
that RNFLT was reduced in particular in the superior quadrant
of the peripapillary retina (26), in addition to changes in macula
thickness and volume (12).
However, conventional TD-OCT technology suffers from tech-
nical inaccuracy due to a lack of exact scan centering around the
optic disk as well as relatively slow scanning speed during image
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acquisition (20, 22). In contrast, latest advances in high-resolution
spectral-domain OCT (SD-OCT) technology providing dramat-
ically increased scanning speed and image resolution combined
with eye-tracking capability already proved to be very helpful in
understanding the observed changes in RNFLT more accurately
thereby avoiding data misinterpretation in the context of complex
neurodegenerative disorders (20, 23, 27).
In order to evaluate the feasibility und usefulness of latest
SD-OCT technology in the diagnostics of AD, we carried out a
preliminary study: (i) to identify a potential RNFLT reduction in
AD patients, (ii) to detect whether this potential RNFLT change
is global or sectoral in nature, and (iii) to compare the effect of
the RNFLT change to SD-OCT standard values provided by the
manufacturer and to age- and sex-matched controls.
MATERIALS AND METHODS
For this study, patients with mild to moderate AD and a cogni-
tively healthy age-matched control subjects were recruited from
the Memory Clinic of the Department of Geriatric Psychiatry of
the Central Institute of Mental Health, Mannheim, Germany. The
research protocol was approved by the Ethics committee II of the
Medical Faculty Mannheim, Ruprecht-Karls-University Heidel-
berg, Mannheim, Germany and followed the recommendations
of the Declaration of Helsinki. Written informed consent was
obtained from each patient, or his/her caregiver (spouse or adult
child), if the patient was incompetent of giving informed con-
sent and from each comparison subject before any examination
procedures were performed.
A physician cooperating with a multi-professional team (neu-
rologists, psychiatrists, psychologists) performed and utilized
diagnostic assessments at the Memory Clinic. The diagnosis of
mild to moderate AD was given to all patients after a detailed
medical history from patient and caregiver; general physical, neu-
rological, and psychiatric examinations demonstrating progressive
cognitive decline which interfered with everyday functioning and
the absence of any neurological or psychiatric disorder possibly
causing dementia (except for AD). Laboratory testing comprising
a CBC with differential counts, syphilis screening, and measures
of serum electrolytes, liver and renal function, cholesterol status,
thyroid function, and serum vitamin B12 and folate levels were
done to exclude secondary causes of dementia. Detailed neuropsy-
chological tests (CERAD test battery WMS-LM, TMT-A, and -B)
provided evidence of cognitive impairment in two or more clin-
ical domains severe enough to cause impairment in activities of
daily living. A structural MRI scan of the brain was performed
in all subjects and, by visual rating, showed evidence of medial
temporal lobe atrophy in the absence of major white matter abnor-
malities and/or other cerebrovascular disorder. In the majority of
patients, CSF analysis revealed a reduction of a-beta42 peptide and
increase of tau and/or phospho-tau protein levels typical for AD.
The study investigated 42 eyes of 22 patients with mild to mod-
erate AD (mean age: 75.9± 6.1 years; 14 women) and 42 eyes of
22 age- and sex-matched healthy controls. Two subjects in either
group had only one eye. The ophthalmologic inclusion criteria
were: (i) best-corrected visual acuity of 0.3 LogMAR or better,
(ii) spherical refraction within ±5.0 diopters (D), (iii) cylindri-
cal correction within ±2.0 D, and (iv) normal results for visual
FIGURE 1 | Comparison of the retinal nerve fiber layer thickness in
different peripapillary sectors: each left column represents the patient
with AD (AD), while the right columns show the values of the control
group (control). The different sectors are labeled as follows: global (G),
nasal superior (NS), nasal (N), nasal inferior (NI), temporal inferior (TI),
temporal (T), and temporal superior (TS). Significant differences (with
Bonferroni correction) were only registered in the nasal superior sector
(P <0.0001), indicated as ***.
field testing (Swedish Interactive Thresholding Algorithm SITA;
Octopus 101 Perimeter; Haag-Streit Deutschland GmbH, Wedel,
Germany). The patients’ history and available medical records
were reviewed for diseases possibly reducing the RNFLT. Patients
with intake history of alcohol abuse, a body mass index >30, and
diseases that could reduce RNFL thickness were excluded from
the study. We also excluded patients with an intraocular pres-
sure ≥21 mmHg, history of glaucoma, anterior ischemic optic
neuropathy, high myopia, prior ocular surgery, and congenital
abnormalities of the optic nerve.
Patients and control subjects underwent various ophthalmic
examinations: (i) assessment of best-corrected visual acuity by
auto-refractometry (auto-refractometer (OCULUS/NIDEK auto-
refractometer, OCULUS Optikgeräte GmbH, Wetzlar, Germany)
followed by subjective refractometry using the ETDRS (Early
Treatment of Diabetic Retinopathy Study) 2000 chart for high-
contrast visual acuity, (ii) slit lamp assisted biomicroscopy of
the anterior segment, (iii) ophthalmoscopy after medical dila-
tion of the pupil, (iv) visual field testing (Swedish Interactive
Thresholding Algorithm SITA; Octopus 101 Perimeter; Haag-
Streit Deutschland GmbH, Wedel, Germany), (v) Goldmann
applanation tonometry, (vi) SD-OCT for RNFL thickness mea-
surement.
The thickness of the RNFL was measured by SD-OCT (Heidel-
berg Spectralis OCT, SPECTRALIS software version 5.3.3.0, EYE
EXPLORER Software 1.6.4.0; Heidelberg Engineering, Heidelberg,
Germany). It obtains non-contact frames in high resolution of
the RNFL. The device is a combination of conventional OCT
technology and confocal scanning laser ophthalmoscopy. A super
luminescence diode is used to emit a laser scan beam with the
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FIGURE 2 | Presentation of the retinal nerve fiber layer thickness
values of the AD eyes compared to the mean of the control eyes. The
different sectors are labeled as follows: global (G, B1), nasal superior (NS,
B2), nasal (N, B3), nasal inferior (NI, B4), temporal inferior (TI, B5),
temporal (T, B6), and temporal superior (TS, B7). A circle represents the
AD eyes. This way, we were able to identify patients with an RNFL
increase or atrophy. We found 67 abnormal sectors and 32 eyes with
pathologic RNFLT (out of 42 eyes).
wavelength of 870 nm. The SD-OCT can receive up to 40,000 A-
scans per second with a depth resolution of 7µm and a transversal
resolution of 14µm. The cSLO uses a laser in order to illuminate
the retina and to scan it point by point to deliver a real-time capture
of the retina. This reference image is linked and saved to the SD-
OCT scan with an eye-tracking system (TrueTrack™, Heidelberg
Engineering, Heidelberg, Germany). Based on eye, an additional
feature – the automatic real-time averaging mode (ART) – results
in even higher quality. First the area of interest is found with cSLO
and then locked. Every time the eye is tracked in the same direction
B scans are taken. Measured data are automatically averaged and
artifacts are minimized. In this study, only high quality data with at
least a total of 18 frames were used to provide the most accurately
result as possible. Due to high-resolution scans, the individual
layers of the RNFL were discriminable – even without pupil dilata-
tion. We first positioned the optic disk perfectly centered and
enabled the ART mode. For each patient, three high resolution
and three high-speed scans were acquired by one examiner to
minimize the variability. All images not reaching our criteria of
quality were dismissed: (i) the fundus had to clear before and dur-
ing image acquisition, (ii) absence of scan and algorithm failures,
(iii) the gray scale saturation of each RNFL needed to be consistent
with a maximum shading of the retinal pigment epithelium, and
(iv) no discontinuation of the scanned layer.
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Table 1 | Comparison of the different sectors around the optic disk
regarding the retinal nerve fiber layer thickness.
Multiple comparison
post test
Mean
diff.
t -Ratio P-value 95% CI of
difference
G_AD versus G_control −7.553 1.874 >0.05 −18.43 to 3.328
NS_AD versus
NS_control*
−21.79 5.407 <0.0001 −32.67 to −10.91
N_AD versus N_control −8.594 2.132 >0.05 −19.47 to 2.287
NI_AD versus
NI_control
0.8693 0.2157 >0.05 −10.01 to 11.75
TI_AD versus TI_control −2.276 0.5646 >0.05 −13.16 to 8.605
T_AD versus T_control −4.875 1.210 >0.05 −15.76 to 6.006
TS_AD versus
TS_control
−11.28 2.798 0.0349 −22.16 to −0.3972
The table shows the mean difference (Mean diff.), the t-ratio, the P-value, and the
95% confidence interval (95% CI). The different sectors are labeled as follows:
global (G), nasal superior (NS), nasal (N), nasal inferior (NI), temporal inferior (TI),
temporal (T), and temporal superior (TS). The one-way ANOVA with Bonferroni’s
Multiple Comparison PostTest showed significant lowering (marked with *) in the
nasal superior sector and the temporal superior sector for AD patients. Due to
Bonferroni correction for multiple comparisons, only the nasal superior sector is
different. All other sectors were not significantly different.
Statistical analysis was carried out using a commercially avail-
able software package (Prism 5 for Mac OSX; GraphPad Software,
Version 5.0c). Mean and standard deviations were presented.
Study and control group were compared with each using one-
way ANOVA with Bonferroni’s Multiple Comparison Post Test.
All P-values were two-tailed and a P-value< 0.05 was considered
to indicate statistical significance.
RESULTS
The study included 22 patients with AD (mean age:
75.9± 6.1 years; age range: 66–88 years; 14 women) and 22 healthy
controls (mean age: 64.0± 8.2; age range: 53–85 years; 15 women)
matched for age and gender with the patients of the study
population.
Using the standard normative database of the SD-OCT device,
the RNFLT measurements compared for each patient of the study
group showed no RNFLT reduction neither globally nor in any
of the peripapillary sectors (P> 0.05) except for one peripapil-
lary sector of one eye where the SD-OCT software identified a
significant reduction in RNFLT (Table 2, Figures 1 and 2). The
mean MMSE score was 22.59± 5.47 in the AD group. The RNFL
thickness measurements compared for each patient (Table 1)
showed a RNFLT reduction of the nasal superior sector in the
AD group (P< 0.0001 by ANOVA using Bonferroni’s correction
Table 2 | Comparison of the different sectors around the optic disk regarding the retinal nerve fiber layer thickness.
Patient Mean NS N NI TI T TS
1 90.0± 8.5 75.0± 1.4 46.0± 9.9 111.5± 21.9 143.5± 9.2 73.0± 1.4 153.0± 17.0
2 102.0± 8.5 105.5± 3.5 60.5± 6.4 112.0± 7.1 166.5± 13.4 77.5± 17.7 157.5± 0.7
3 100.0± 0.0 99.0± 4.2 99.5± 0.7 127.5± 2.1 130.5± 2.1 61.5± 0.7 122.5± 0.7
4 99.0 124.0 92.0 127.0 134.0 58.0 108.0
5 110.0± 5.7 116.5± 4.9 81.0± 5.7 129.0± 4.2 148.5± 2.1 86.5± 13.4 151.0± 5.7
6 95.5± 4.9 110.5± 16.3 66.0± 2.8 91.5± 21.9 143.5± 23.3 68.0± 1.4 148.5± 14.8
7 108.0± 1.4 111.5± 16.3 87.0± 0.0 125.5± 4.9 147.5± 3.5 77.5± 4.9 139.0± 0.0
8 85.0± 1.4 85.5± 4.9 55.0± 1.4 73.0± 5.7 129.0± 9.9 81.5± 20.5 118.5± 7.8
9 90.5± 2.1 91.5± 7.8 67.0± 2.8 80.5± 2.1 147.0± 4.2 66.0± 0.0 139.0± 11.3
10 93.0± 0.0 110.0± 0.0 66.5± 0.7 124.0± 5.7 141.5± 7.8 59.5± 0.7 114.5± 0.7
11 91.5± 9.2 115.5± 17.7 65.0± 8.5 119.0± 5.7 119.0± 8.5 60.0± 5.7 126.0± 26.9
12 113.0 118.0 99.0 155.0 153.0 69.0 145.0
13 94.0± 0.0 118.0± 0.0 58.5± 0.7 82.0± 1.4 143.5± 3.5 81.0± 4.2 128.5± 0.7
14 97.5± 4.9 78.5± 10.6 61.5± 12 109.0± 11.3 154.5± 7.8 94.5± 3.5 124.5± 10.6
15 87.0± 0.0 79.5± 3.5 75.5± 4.9 91.0± 2.8 116.5± 9.2 83.0± 5.7 93.0± 11.3
16 103.0± 1.4 120.5± 12 79.5± 3.5 137.5± 7.8 134.0± 0.0 67.5± 0.7 139.0± 1.4
17 91.0± 0.0 92.0± 0.0 71.5± 3.5 112.5± 7.8 134.0± 2.8 61.0± 7.1 126.0± 1.4
18 136.5± 27.6 145.0± 53.7 117.5± 20.5 179.0± 12.0 204.0± 6.4 81.5± 20.5 165.5± 65.1
19 125.5± 1.4 136.5± 4.2 90.0± 10.6 145.5± 12.7 182.0± 3.5 93.5± 5.7 173.5± 7.1
20 137.0± 2.8 149.5± 7.8 102.0± 6.4 139.5± 10.6 194.5± 1.4 103.5± 2.1 200.5± 5, 7
21 120.0± 2.1 170.5± 15.6 98.5± 1.4 130.5± 14.8 151.5± 4.2 78.0± 2.1 154.0± 12.0
22 141.0± 0.0 151.5± 17.0 108.0± 2.1 162.5± 15.6 198.0± 10.6 98.0± 5.7 204.5± 16.3
Controls 101.8± 10.7 122.8± 28.1 79.0± 12.8 107.5± 27.2 138.4± 19.9 74.3± 11.8 139.3± 23.3
Heidelberg spectralis values (P<0.01) 94.5± 20.5 71.5± 33.5 102.0± 44.0 103.0± 52.0 135.0± 43.0 69.5± 27.5 129.0± 38.0
The table shows the mean of both eyes and SD interval for every AD patient (in case the patient has only one eye SD is not presented). At the bottom of the table
means of the control patients as well the normative data of the manufacture (kindly provided) are viewed.The different sectors are labeled as follows: global (G), nasal
superior (NS), nasal (N), nasal inferior (NI), temporal inferior (TI), temporal (T), and temporal superior (TS).
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for multiple comparisons). Every other sector and global RNFLT
was not significant different. The P-value for the temporal supe-
rior sector showed a tendency of significance (P= 0.0349) after
Bonferroni correction for multiple comparisons. In all other
cases, the P-value was clearly above 0.05. Neither age or gen-
der nor known disease duration or AD stage was significantly
correlated with RNFLT. Alzheimer patients had a significantly
increased cup-to-disk ratio (CD-ratio) compared with controls
(P = 0.001, Figure 3). However the CD-ratio did not correlate
with the RNFLT.
However, to compare the RNFLT globally and in each sec-
tor further in more detail, we used a modified model described
earlier (29). Namely, we plotted every measured value for each
eye with a different plot for each sector (Figure 2). We used
the calculated mean from the control group to show the differ-
ence between AD patients and our sex-, and age-matched healthy
control group. As previously described (30), there is a normal
inter-individual variation in RNFLT, above +2SD increase of
RNFLT compared to reported RNFLT normal values, and the
values below −1SD as RNFL decrease or atrophy. Those two bor-
ders (+2SD and −1SD) were also plotted to show deviations.
This way, we were able to identify patients with RNFL atro-
phy and measure the affected sectors (Table 3). Our age- and
sex-matched-based model marked 32 out of 42 eyes (76.19%)
as pathologic with 67 abnormal sectors. Nonetheless, despite
using our advanced age-, and gender-matched measurement
model no RNFL loss was evident in four patients (18.18%)
and one eye of additional three patients (7.14% of total eye
number).
DISCUSSION
Our results show a significant reduction of the RNFLT in the nasal
superior sector in AD patients compared to age- and sex-matched
controls. Globally and in all other sectors, there was no significant
change detectable. The CD-ratio was significantly increased in AD
patients.
Retinal nerve fiber layer thickness in AD patients has already
been examined by different techniques: histopathological studies
examining the RNFL of AD patients and controls post-mortem
have yielded different results: while some of them did not report
changes in the RNFLT at all (24, 25), others showed significant
reductions (31–35). Blanks et al. reports a loss of 25% in the
ganglion cell layer (34), although amyloid deposits and neurofib-
rillary tangles, the typical hallmarks of AD, were not found (31,
32). Earlier studies using OCT technology provided preliminary
evidence that AD decreases the RNFLT (11–13, 26, 36–38). One
meta-analysis (39) claimed to show a significant decrease in global
RNFLT. However, due to the selection bias of the different studies
and as the global reduction in some of the included study was
mostly subtle, individual peripapillary sectors of the circumfer-
ential scans were examined as well in our study. Parisi et al. and
Iseri et al. found that all sectors were decreased significantly. In
contrast, other studies detect a decrease only in the superior and
inferior sector (13, 38), or just in the superior sector (26). Several
studies have shown that the CD-ratio is increased in AD patients
(33, 38), furthermore it seems that due to studies the CD-ratio
correlates with the RNFLT (40).
FIGURE 3 | Comparison of the cup-to-disk ratio (CD-ratio) between AD
patients (AD) and controls (control) with a significant difference
(P =0.001) indicated as **. The mean CD-ratio of AD patients was 0.396,
the one of the control patients 0.359.
The different findings in histopathologic studies may be
explained by different post-mortem evaluation techniques or
diagnostic selection criteria. The disagreement in OCT studies may
evolve from divergent stages of the disease as well as technical inac-
curacy of OCT studies. Furthermore, the sample sizes of the studies
cited were fairly low (mean number of AD patients: 16.9± 7.1).
There is some evidence that the RNFLT may decrease with advanc-
ing disease (12). The patients with a decrease in every quadrant
(global reduction in RNFLT) had fairly low MMSE scores, rang-
ing from 11 to 19 (36) and from 8 to 28 (27). In comparison, the
patients of the study of Berisha et al. had MMSE scores between
17 and 30 (26) and experienced a decrease only in the superior
sector. Furthermore, the superior sector could be used to dis-
criminate between MCI and severe AD (13), while there was no
significant difference found between the RNFLT of MCI and mild
AD patients (11).
As our study included a comparatively large number of par-
ticipants and used latest high-resolution SD-OCT technology,
we are able to extend the current evidence. (1) Our patients
did not suffer from severe AD, thus the score of MMSE did
not correlate with the RNFLT. (2) The reduction of RNFLT
in an isolated peripapillary sector may be the first sign of an
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Table 3 | Comparison of the different sectors around the optic disk regarding the retinal nerve fiber layer thickness (RNFLT) in the eyes of AD
patients.
Patient MMSE Clinical dementia
rating
Disease duration
(months)
Cup-to-disk ratio
(left eye first)
SD-OCT
calculations
Age- and sex-matched
calculations
Left eye Right eye Left eye Right eye
1 17 2 3.2 0.40, 0.43 0 0 2 Atrophic 2 Atrophic
2 27 1 2.6 0,41, 0.38 0 0 1 Atrophic 1 Atrophic
3 20 2 6.9 0.40, 0.38 0 0 1 Atrophic 1 Atrophic
4 23 1 3 0.44, – 0 0 2 Atrophic –
5 25 0.5 4 0.44, 0.45 0 – 0 0
6 23 1 7.4 0.43, 0.40 0 0 1 Atrophic 1 Atrophic
7 25 1 11 0.38, 0.35 0 0 0 0
8 29 0.5 6.3 0.44, 0.41 0 0 3 Atrophic 4 Atrophic
9 19 2 1.2 0.35, 0.29 0 0 2 Atrophic 1 Atrophic
10 20 2 18.3 0.33, 0.28 0 0 2 Atrophic 3 Atrophic
11 27 0.5 8.7 0.40, 0.40 0 0 0 4 Atrophic
12 30 0,5 32 –, 0.35 – 0 – 0
13 25 0.5 32.2 0.33, 0.40 0 1 Swollen 1 Atrophic 1 Atrophic
14 29 0.5 22.5 0.35, 0.35 0 0 1 Atrophic 2 Atrophic
15 28 0.5 6.5 0.33, 0.31 0 1 Atrophic 3 Atrophic 2 Atrophic
16 29 0.5 24.5 0.35, 0.35 0 0 0 0
17 21 1 8.5 0.45, 0.45 0 0 2 Atrophic 1 Atrophic
18 21 1 8.0 0.44, 0.44 4 Atrophic 0 4 Atrophic 0
19 14 2 6.6 0.37, 0.42 0 0 4 Atrophic 2 Atrophic
20 21 2 7.3 0.38, 0.33 0 0 0 3 Atrophic
21 13 2 63.3 0.35, 0.41 0 0 3 Atrophic 5 Atrophic
22 11 2 7.9 0.33, 0.40 0 0 1 Atrophic 1 Atrophic
Abnormal eyes 1 2 16 16
Abnormal sectors 4 2 33 34
The first column shows the patient number, the second displays the reached points of the MMSE, the third column the Clinical Dementia Rating score, the fourth
the months since diagnosis and the fifth the cup-to-disk ratio. The two blocks following show the data as obtained from the SD-OCT-based internal database (this is
plotted for left and right eye).This was put into contrast to our calculations using age- and sex-matched controls (the two following blocks). At the bottom of this table,
the count of the pathologic peripapillary sectors as well as eyes is shown. Thus the SD-OCT’s internal database was not able to detect 61 abnormal sectors and 29
eyes with pathologic RNFLT compared to our age- and sex-matched based model.
affection of RNFL in AD, which extends over the remaining sec-
tors (and/or globally) in the course of AD, as described by others.
(3) The heterogeneity of AD may finally contribute to com-
pletely unaffected visual systems in some patients, as we could
demonstrate, too.
The limitations of this study are: (i) that only patients with
a limited range of severity of AD were included and (ii) that
only cross-sectional measurements were done without follow-up
to investigate a potential progress of the RNFLT. On the other
hand the strengths of our study are: (i) that patients and controls
were age- and sex-matched, (ii) high-resolution SD-OCT mea-
surements were obtained, (iii) and the clinical diagnosis of AD was
obtained in a specialized memory clinic by using highly standard-
ized clinical criteria including neuropsychological assessments and
biomarkers (MTA, CSF).
In summary, we demonstrate that mild to moderate stages of
AD may be associated with a reduction of RNFLT in the nasal supe-
rior sector. However, it remains unclear whether RNFLT analysis
is an appropriate method for monitoring disease progression, if
all AD patients are affected. Prerequisite for the interpretations
of OCT-investigations are standardized technical requirements
provided by latest SD-OCT technology.
REFERENCES
1. Neuropathology Group. Medical Research Council Cognitive Function and
Aging Study. Pathological correlates of late-onset dementia in a multicentre,
community-based population in England and Wales. Neuropathology Group
of the Medical Research Council Cognitive Function and Ageing Study (MRC
CFAS). Lancet (2001) 357:169–75. doi:10.1016/S0140-6736(00)03589-3
2. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau
P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet
Neurol (2010) 9:1118–27. doi:10.1016/S1474-4422(10)70223-4
3. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al.
The diagnosis of dementia due to Alzheimer’s disease: recommendations from
the National Institute on Aging-Alzheimer’s Association workgroups on diag-
nostic guidelines for Alzheimer’s disease. Alzheimers Dement (2011) 7:263–9.
doi:10.1016/j.jalz.2011.03.005
4. Jagust WJ, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging
evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol (2006)
59:673–81. doi:10.1002/ana.20799
5. Davatzikos C, Resnick SM, Wu X, Parmpi P, Clark CM. Individual patient diag-
nosis of AD and FTD via high-dimensional pattern classification of MRI. Neu-
roimage (2008) 41:1220–7. doi:10.1016/j.neuroimage.2008.03.050
Frontiers in Psychiatry | Neurodegeneration February 2014 | Volume 5 | Article 22 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kromer et al. RNFL defects in Alzheimer’s disease
6. Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, et al. Dimin-
ished glucose transport in Alzheimer’s disease: dynamic PET studies. J Cereb
Blood Flow Metab (1991) 11:323–30. doi:10.1038/jcbfm.1991.65
7. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al.
Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease.
Brain (2006) 129:2856–66. doi:10.1093/brain/awl178
8. Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G. Amyloid and tau imag-
ing, neuronal losses and function in mild cognitive impairment. J Nutr Health
Aging (2008) 12:61S–5S. doi:10.1007/BF02982589
9. Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blanken-
stein MA, et al. CSF biomarker levels in early and late onsetalzheimer’s disease.
Neurobiol Aging (2009) 30:1895–901. doi:10.1016/j.neurobiolaging.2008.02.007
10. Diniz BSO, Pinto Júnior JA, Forlenza OV. Do CSF total tau, phosphorylated tau,
and beta-amyloid 42 help to predict progression of mild cognitive impairment
to Alzheimer’s disease? A systematic review and meta-analysis of the literature.
World J Biol Psychiatry (2008) 9:172–82. doi:10.1080/15622970701535502
11. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal
thickness in patients with mild cognitive impairment and Alzheimer’s disease.
Neurosci Lett (2007) 420:97–9. doi:10.1016/j.neulet.2007.02.090
12. Iseri P, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment
and retinal morphological and visual functional abnormalities in Alzheimer
disease. J Neuroophthalmol (2006) 26:18–24. doi:10.1097/01.wno.0000204645.
56873.26
13. Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness
in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurol
Neurosurg (2011) 113:523–6. doi:10.1016/j.clineuro.2011.02.014
14. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Opti-
cal coherence tomography. Science (1991) 254:1178–81. doi:10.1126/science.
1957169
15. Schuman JS, Pedut-Kloizman T, Pakter HM, Wang N, Guedes V, Huang L, et al.
Optical coherence tomography and histologic measurements of nerve fiber layer
thickness in normal and glaucomatous monkey eyes. Invest Ophthalmol Vis Sci
(2007) 48:3645–54. doi:10.1167/iovs.06-0876
16. Guedes V, Schuman JS, Hertzmark E, Wollstein G, Correnti A, Mancini R, et al.
Optical coherence tomography measurement of macular and nerve fiber layer
thickness in normal and glaucomatous human eyes. Ophthalmology (2003)
110:177–89. doi:10.1016/S0161-6420(02)01564-6
17. Hee MR, Izatt JA, Swanson EA, Huang D, Schuman JS, Lin CP, et al. Opti-
cal coherence tomography of the human retina. Arch Ophthalmol (1995)
113:325–32. doi:10.1001/archopht.1995.01100030081025
18. Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Schuman JS, et al. Optical
coherence tomography of macular holes. Ophthalmology (1995) 102:748–56.
doi:10.1016/S0161-6420(95)30959-1
19. Krivoy D, Gentile R, Liebmann J, Stegman Z, Walsh J, Ritch R. Imaging con-
genital optic disc pits and associated maculopathy using optical coherence
tomography. Arch Ophthalmol (1996) 114:165–70. doi:10.1001/archopht.1996.
01100130159008
20. Serbecic N, Beutelspacher SC, Kircher K, Reitner A, Schmidt-Erfurth U. Inter-
pretation of RNFLT values in multiple sclerosis-associated acute optic neuri-
tis using high-resolution SD-OCT device. Acta Ophthalmol (2010) 90:540–5.
doi:10.1111/j.1755-3768.2010.02013.x
21. Serbecic N, Aboul-Enein FC, Beutelspacher SC, Graf M, Kircher K, Geitzenauer
W, et al. Heterogeneous pattern of retinal nerve fiber layer in multiple sclerosis.
High resolution optical coherence tomography: potential and limitations. PLoS
One (2010) 5:e13877. doi:10.1371/journal.pone.0013877
22. Serbecic N, Beutelspacher SC, Aboul-Enein FC, Kircher K, Reitner A, Schmidt-
Erfurth U. Reproducibility of high-resolution optical coherence tomography
measurements of the nerve fibre layer with the new Heidelberg Spectralis opti-
cal coherence tomography. Br J Ophthalmol (2011) 95:804–10. doi:10.1136/bjo.
2010.186221
23. Serbecic N, Aboul-Enein FC, Beutelspacher SC, Vass C, Kristoferitsch W, Lass-
mann H, et al. High resolution spectral domain optical coherence tomography
(SD-OCT) in multiple sclerosis: the first follow up study over two years. PLoS
One (2011) 6:e19843. doi:10.1371/journal.pone.0019843
24. Curcio CA, Drucker DN. Retinal ganglion cells in Alzheimer’s disease and aging.
Ann Neurol (1993) 33:248–57. doi:10.1002/ana.410330305
25. Davies DC, McCoubrie P, McDonald B, Jobst KA. Myelinated axon number in
the optic nerve is unaffected by Alzheimer’s disease. Br J Ophthalmol (1995)
79:596–600. doi:10.1136/bjo.79.6.596
26. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormal-
ities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci (2007) 48:2285–9.
doi:10.1167/iovs.06-1029
27. Valenti DA. Neuroimaging of retinal nerve fiber layer in AD using optical coher-
ence tomography. Neurology (2007) 69:1060. doi:10.1212/01.wnl.0000280584.
64363.83
28. Beutelspacher SC, Serbecic N, Hausner L, Kromer R, Aboul-Enein FC, Froehlich
L, et al. Detection of retinal nerve fibre layer defects in Alzheimers dementia
using SD-OCT. Acta Ophthalmol (2011) 89:0–0. doi:10.1111/j.1755-3768.2011.
2262.x
29. Serbecic N, Beutelspacher SC, Geitzenauer W, Kircher K, Lassmann H, Reitner
A, et al. RNFL thickness in MS-associated acute optic neuritis using SD-OCT:
critical interpretation and limitations. Acta Ophthalmol (2011) 89:e451–60.
doi:10.1111/j.1755-3768.2011.02134.x
30. Funaki S, Shirakashi M, Funaki H, Yaoeda K, Abe H. Relationship between age
and the thickness of the retinal nerve fiber layer in normal subjects. Jpn J Oph-
thalmol (1999) 43:180–5. doi:10.1016/S0021-5155(99)00015-5
31. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degenera-
tion in Alzheimer’s disease. N Engl J Med (1986) 315:485–7. doi:10.1056/
NEJM198608213150804
32. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer’s disease. Ophthalmology
(1990) 97:9–17. doi:10.1016/S0161-6420(90)32621-0
33. Tsai CS, Ritch R, Schwartz B, Lee SS, Miller NR, CHI T, et al. Optic-nerve
head and nerve-fiber layer in Alzheimer’s-disease. Arch Ophthalmol (1991)
109:199–204. doi:10.1001/archopht.1991.01080020045040
34. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer’s
disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging (1996)
17:377–84. doi:10.1016/0197-4580(96)00010-3
35. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal
pathology in Alzheimer’s disease. II. Regional neuron loss and glial changes in
GCL. Neurobiol Aging (1996) 17:385–95. doi:10.1016/0197-4580(96)00010-3
36. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morpho-
logical and functional retinal impairment in Alzheimer’s disease patients. Clin
Neurophysiol (2001) 112:1860–7. doi:10.1016/S1388-2457(01)00620-4
37. Parisi V. Correlation between morphological and functional retinal impair-
ment in patients affected by ocular hypertension, glaucoma, demyelinating
optic neuritis and Alzheimer’s disease. Semin Ophthalmol (2003) 18:50–7.
doi:10.1080/08820530390897855
38. Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, et al. Retinal nerve fiber layer
structure abnormalities in early Alzheimer’s disease: evidence in optical
coherence tomography. Neurosci Lett (2010) 480:69–72. doi:10.1016/j.neulet.
2010.06.006
39. He X-F,LiuY-T,Peng C,Zhang F,Zhuang S,Zhang J-S. Optical coherence tomog-
raphy assessed retinal nerve fiber layer thickness in patients with Alzheimer’s
disease: a meta-analysis. Int J Ophthalmol (2012) 5:401–5. doi:10.3980/j.issn.
2222-3959.2012.03.30
40. Wang YX, Pan Z, Zhao L, You QS, Xu L, Jonas JB. Retinal nerve fiber layer
thickness. The Beijing Eye Study 2011. PLoS One (2013) 8:e66763. doi:10.1371/
journal.pone.0066763
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 20 October 2013; accepted: 11 February 2014; published online: 25 February
2014.
Citation: Kromer R, Serbecic N, Hausner L, Froelich L, Aboul-Enein F and Beu-
telspacher SC (2014) Detection of retinal nerve fiber layer defects in Alzheimer’s disease
using SD-OCT. Front. Psychiatry 5:22. doi: 10.3389/fpsyt.2014.00022
This article was submitted to Neurodegeneration, a section of the journal Frontiers in
Psychiatry.
Copyright © 2014 Kromer, Serbecic , Hausner, Froelich, Aboul-Enein and Beu-
telspacher. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
www.frontiersin.org February 2014 | Volume 5 | Article 22 | 7
